Investment Pitches

Pitch Summary:
Palantir Technologies is positioned as a leader in integrating AI with its Foundry platform, creating a unique 'nervous system' for enterprises. Despite its technological edge and significant growth potential, the stock is currently overvalued with a P/E ratio of 236, suggesting that much of the anticipated growth is already priced in. The recommendation is to hold existing shares but refrain from new purchases unless the price drops below $150.

BSD Analysis:
Palantir's Foundry platform, enhanced by AI, offers a breakthrough service by connecting disparate data sources into a coherent system, creating a 'Digital Twin' for enterprises. This positions Palantir advantageously in the corporate sector, where efficiency gains are highly sought after. However, the company's high market capitalization and P/E ratio indicate that the stock is priced for perfection, with significant growth already factored in. While Palantir has a technological lead, competitors like Microsoft are entering the market, potentially narrowing Palantir's window of opportunity. Additionally, macroeconomic factors such as high Fed rates and conservative corporate management could slow adoption. Thus, while the business is poised for growth, the stock's current valuation suggests caution.

Pitch Summary:
Amazon's underperformance in 2024 presents a buying opportunity as its fundamentals remain strong, particularly with advancements in AI and AWS. The company's AI developments are underestimated by the market, and its AWS business continues to grow, providing a competitive advantage.

BSD Analysis:
Amazon's AWS segment is expected to drive future growth, particularly with its AI advancements and infrastructure improvements. The company's strategic focus on developing its own AI chips, like Trainium, and expanding its cloud services for government clients could significantly enhance its market position. Despite high CAPEX and valuation concerns, Amazon's return on invested capital has improved, supporting its premium valuation. The potential for AWS to capture market share from competitors like Palantir in government contracts could further boost Amazon's growth prospects. Risks include slower-than-expected AI project monetization and potential market rotations away from AI-focused stocks.

Pitch Summary:
STWD offers a stable dividend yield of over 10%, making it an attractive income investment. The company's consistent dividend payments over the past decade highlight its strong cash flow management and resilience in the real estate sector.

BSD Analysis:
Starwood Property Trust's focus on commercial real estate debt positions it well to capitalize on opportunities in a recovering market. The REIT's ability to maintain a high dividend yield underscores its robust cash flow and prudent management. With interest rates potentially stabilizing, STWD's income potential remains strong. The company's strategic acquisitions and management of commercial mortgage loans provide a buffer against market volatility. Investors seeking high yield and stability in the real estate sector should consider STWD as a core holding, especially during periods of market uncertainty.

Pitch Summary:
AMLP offers a yield exceeding 8%, making it a compelling choice for income investors. It serves as a proxy for pipeline investments, avoiding the tax complexities of K-1 forms, and is positioned to benefit from undervaluation in the energy sector.

BSD Analysis:
AMLP's focus on energy infrastructure MLPs provides investors with exposure to a sector poised for recovery. The ETF's avoidance of K-1 forms simplifies tax reporting, making it attractive for retail investors. With energy transfer and enterprise products partners seen as undervalued, AMLP offers a strategic entry point into the sector. The ETF's high yield is supported by stable cash flows from energy infrastructure, providing a hedge against inflation. As energy markets stabilize, AMLP's potential for capital appreciation alongside income generation makes it a valuable addition to income-focused portfolios.

Pitch Summary:
The Goldman Sachs Nasdaq-100 Premium Income ETF offers a 9.8% yield over the past year, making it an attractive income-generating investment. Its selective call option strategy provides a balance of income and potential appreciation.

BSD Analysis:
GPIQ's strategy of leveraging call options on the Nasdaq-100 index allows it to generate significant income while maintaining exposure to tech-heavy growth. The ETF's construction is designed to capitalize on market volatility, offering a stable yield in uncertain times. As the market retraced following NVIDIA's earnings, GPIQ's income-focused approach remains appealing for investors seeking yield. The fund's ability to adapt its strategy to market conditions suggests it can continue to deliver attractive returns. Investors should consider adding GPIQ on market pullbacks to benefit from its income potential and strategic positioning.

Pitch Summary:
NVIDIA reported a 63% year-over-year revenue increase, showcasing strong performance despite market volatility. The company's earnings exceeded expectations, but the stock sold off due to broader market risk-off sentiment.

BSD Analysis:
NVIDIA's impressive revenue growth highlights its pivotal role in the AI revolution, which continues to drive demand for its GPUs. Despite the market's initial negative reaction, likely due to concerns over depreciation schedules and broader economic conditions, NVIDIA's fundamentals remain strong. The company's strategic positioning in AI and data centers suggests continued growth potential. However, macroeconomic factors, such as rising unemployment and potential Fed rate decisions, could impact market sentiment. Investors should consider NVIDIA's long-term growth trajectory in AI and automation as a compelling reason to hold or accumulate shares during market pullbacks.

Pitch Summary:
@capybaraReborn presents a strongly critical analysis of ETHZ’s board compensation plan, arguing that massive equity issuance has resulted in extreme dilution and egregious overpayment to directors. The post quantifies how a large portion of NAV per share was effectively transferred from shareholders to board members. Compensation levels are compared unfavorably to S&P 500 standards, highlighting severe governance misalignment for a small-cap company. The author emphasizes that shareholder backlash is widespread and that active efforts are underway to reverse or fix the compensation structure. While long-term optimism is implied if governance is corrected, the current setup is framed as unacceptable and value-destructive.

BSD Analysis:
The pitch relays a sharply critical assessment of $ETHZ (ETHZ) focused on governance and board compensation. The core allegation is that an outsized equity-based compensation plan has driven severe shareholder dilution, effectively transferring a meaningful portion of NAV per share from owners to directors. Board pay is characterized as egregious and wildly disproportionate when benchmarked against S&P 500 standards, despite ETHZ being a small-cap entity. The author argues this represents a fundamental misalignment of incentives and a breakdown in stewardship. Shareholder dissatisfaction is described as broad and growing, with active efforts underway to challenge, reverse, or restructure the compensation framework. While the underlying asset value could support long-term optimism if governance is repaired, the current situation is framed as acutely value-destructive and unacceptable.

Actual Post Content:
Here’s some interesting math. Under $ETHZ current comp plan, ~5mln shares were issued against roughly ~14mln pre-dillution shares. 4 board directors, who have a fiduciary duty to act in best interests of shareholders received ~3.2mln shares, or $51mln at the time of issue, an average of just under $1 per share for each director. So if you take the amount of shares you have, that is how much you personally have paid out of your NAV/share each one of the board directors. Now with my ~480k shares, that means I effectively paid each board director near half a million dollars to be on the board out of my own pocket. The average pay for a board member of a SP500 company is $350k-400k per year. Surely if it’s enough for a billion dollar company, it’s enough for a small cap like $ETHZ. So then if my share of NAV/share lost alone covers typical board compensation on the very high end, it begs the question how come all other shareholders were taxed like this as well. The fact the board was given 50x compensation of SP500 companies and over 100x of DAT piers, is one key reason why nearly all large shareholders are actively working to get this comp plan situation fixed and why it will be fixed anyway, in any outcome. We’re waiting to get this mess behind us to move on to better and bigger things together as a company that will emerge stronger out of this than it was before.

URL: https://x.com/capybaraReborn/status/1993635284366270974

Pitch Summary:
@bingbingbom presents a highly technical, multi-part thread on $TECX and its lead asset TX45, an Fc-relaxin fusion for HFpEF with Group 2 pulmonary hypertension, specifically the CpcPH subset. The core thesis is that prior relaxin programs failed because they treated broad HFpEF “blobs” dominated by IpcPH, whereas TX45 is targeting the only sensible group — CpcPH, where both PCWP and PVR are high and there is true pulmonary vascular disease. The author walks through two safety concerns: lowering PVR in Group 2 PH without precipitating pulmonary edema and the risk of RV ischemia from “coronary steal,” arguing that Phase 1b data (≈-19% PCWP, ≈+18.5% CO, ≈–1–2% MAP) support a favorable hemodynamic profile. They then introduce three major variables: RXFP1 downregulation (limiting the maximal effect vs Phase 1b), LA stiffness (a “compliance tax” that shrinks the PCWP benefit), and FcRn saturation making q4w dosing pharmacokinetically fragile with low troughs. Using an operational model of agonism and receptor density assumptions, they haircut the Phase 1b PVR effect from –35.5% to a more realistic mid-20s percent drop for Phase 2. They also derive a “drag coefficient” mapping % PVR reduction to 6MWT meters, concluding that drug-mediated vasodilation converts only ~40–50% of the theoretical mechanical benefit into functional gains, implying an expected +~23 m 6MWT improvement. Renal benefits are viewed as short-term optics (“renal fatigue”), with eGFR bumping early then flattening by 12–24 weeks. Putting it all together, they expect Phase 2 ΔPVR –22% to –26% with ~85% probability of statistical success, and 6MWT +21–28 m with ~60% probability of a clean win. The conclusion is that TX45 “prob works (pvr & 6mwt win)” and APEX likely passes on both hemodynamics and function, but upside is capped by receptor biology, chamber stiffness, and q4w PK limits.

BSD Analysis:
TX45 sits in a high-value niche: Group 2 PH due to HFpEF in the CpcPH subset, where both elevated PVR and structural vascular disease create room for a targeted hemodynamic and anti-fibrotic agent. Mechanistically, an Fc-relaxin fusion that engages RXFP1 and delivers “triple unloading” (lower PCWP, PVR, and SVR) is exactly the kind of profile you would want for this pathophysiology, and the Phase 1b hemodynamics are appropriately described as impressive. The thread does an unusually thorough job of marking down the initial enthusiasm by incorporating receptor downregulation, left-atrial stiffness, FcRn saturation, and a realistic drag factor when translating PVR changes into 6MWT gains. Even after those haircuts, a mid-20s percent reduction in PVR with a roughly +20–25 m 6MWT improvement would still be clinically meaningful in a well-phenotyped CpcPH population, especially if safety remains benign and edema rates are low. The real risk is not binary failure but landing in an intermediate zone where TX45 is clearly active yet underwhelming on function, making pricing and broad adoption more challenging. PK fragility with q4w dosing, the noise floor around 6MWT, and the need for tight CpcPH enrichment put a lot of weight on trial design details that investors often gloss over. On the other hand, if the hemodynamic effect translates cleanly and functional data clear the “not just noise” bar, the asset could anchor a first-in-class franchise in a segment with limited competition. From a risk-reward perspective, TX45 looks like a high-beta cardio-pulmonary program where the probability of some level of success is fairly high, but the distribution of outcomes ranges from modestly positive to genuinely franchise-defining. Execution around dosing, patient selection, and endpoint timing will decide which end of that distribution shareholders actually realize.

Actual Post Content:
tx45 = relaxin fc fusion for hfpef + group 2 ph, specifically the cpcph slice. relaxin biologically sound but failed in trials bc: 1. they treated the wrong pts (broad hfpef loaded with ipcph who cannot benefit from pvr lowering). 2. they used molecules with bad pk / tissue issues (charge, distribution, hpoten, edema, etc. tx45 pitch: target the right pheno, focus on cpcph, where pcwp is high (stiff lv/la), and pvr is high (real pulmonary vascular disease). this is where a relaxin-like drug has something meaningful tfix. we see “triple unloading”: decrease pcwp ->less la/lv congestion, decrease pvr ->the rv has lower afterload, decrease svr ->lv sees less afterload, co goes up. group 2 ph = ph from left heart disease (hfpef here). cpcph = double hit same stiff lv / high pcwp plus remodeled pulmonary arterioles (smooth muscle, fibrosis) and high pvr (>2–3 wu) ->true pulmonary vascular disease. what we see from tx45 p1b (cpcph cohort): pcwp decrease ~ 19% cincrease ~ 18.5% map decrease ~ 1–2% (basically flat). net net, tx45 looks safe in principle. this is the first big hidden headwind: the bullish story assumes “tx45 sees normal receptor density, sthe p1b pvr drop is representative of p2.” sthe realistic p2 ceiling is: mid-20s % drop in pvr, not –35%+. net net: primary – Δpvr expected range: –22% to –26% probability of stat success: ~85% net net: very likely positive. key secondary – Δ6mwt expected: +21–28 m, central ~+23 m probability of a clean statistical win: ~60% signal vs noise (15–20 m floor): ~1.5x. so: yes, apex is likely to pass on pvr and prob on 6mwt. tx45 almost certainly has real drug effect in cpcph. but: rxfp1 downreg + stiff la cap the upside. fcrn saturation makes q4w dosing pk-fragile (low troughs). long-term renal issues.

URL: https://x.com/bingbingbom/status/1993398655689408800

Pitch Summary:
In our last letter, we pondered the risk of an “AI Air Pocket” as market participants digest a growing gap between AI infrastructure capex and the demonstrable return on those investments. That scepticism has intensified in the last couple of weeks, alongside a general apprehension about the US economy and the government shutdown. For perspective, at the end of the quarter, we had 41% exposure to North America — dominant enough to make macro matter, even if we spend most of our time thinking in micro. We have been “AI bulls” for a long time, investing in NVIDIA before ChatGPT entered the zeitgeist, and, five years on, we remain firmly convinced this is a multi-decade technology epoch. That said, our enthusiasm has become more discriminating about where we place our bets. What has really sharpened our discernment is OpenAI’s recent deal-making. The size, structure, and implied capacity behind these announcements have blown past even the upper bounds of our internal assumptions.

BSD Analysis:
NVIDIA is the unassailable, high-margin kingmaker of the AI revolution, converting its technological dominance into a grotesque amount of cash flow. Its true moat is not just its GPUs, but the CUDA software ecosystem, which locks in every hyperscaler and AI lab with high switching costs that are virtually unbreachable. Bears continue to scream "AI bubble," but their argument is fundamentally flawed: the demand is sustained by the increasing complexity of models (like OpenAI's Q1 and Q3), which demand exponentially more compute intensity, confounding the "AI efficiency" bears. With triple-digit data center revenue growth and gross margins exceeding 70%, NVIDIA's premium valuation is utterly justified by its strategic position, cash generation, and multi-year backlog. The stock is a core holding for anyone looking for leveraged exposure to the trillions of dollars of value that AI is set to unlock.

Pitch Summary:
Timee (215A.T): Timee operates a short-term job marketplace in Japan. We’ve been investors for over a year, and it’s our first investment in the country. I’m excited by its prospects, as the company showcases all the hallmarks of a leading two-sided, asset-light, marketplace. It’s an archetype for one of the world’s best business models, one where we’ve historically found some of our best investments. Japan is in the early stages of a chronic labor shortage, one that’s predicted to get worse over the next few decades. A declining birth rate, and increasing elderly population, means Japan will be missing -3.4M workers by 2030, rising to -11M by 2040 (~3% and ~10% of Japan’s current adult population). Most of these shortages are in Timee’s key categories – with 1.6M “missing workers” across logistics, food, and retail today11. It’s extremely difficult to find qualified part-time or full-time service workers in Japan – and it will only grow more difficult over time. In 2018, the Japanese government began promoting “働き方改革” or “work-style reform”, to address these issues. This initiative encouraged side-jobs / multiple jobs, and normalized the practice. 11 There’s only a total -370K missing workers today by Timee’s calculations vs. Recruit’s ~633K estimate. It was founded in 2017 by Ryo Ogawa, and pioneered a new labor category in Japan – instant, on-demand staffing. When a business urgently needs a cashier, warehouse worker, waitress, or a variety of other service jobs to be filled, they can post on Timee’s platform and have someone start as soon as the same day. Through Timee’s app, companies can post shifts as short as one hour – for example, a restaurant or retail shop can fill a sudden staffing gap – and workers can sign up in real time, without interviews or resumes. Instead, trust is built upon a “rating” system and work history – with employees earning “badges” after showing excellence in a particular area. For example, a worker who receives repeat positive reviews after working in “dish-washing”, “cooking” or “shelf-stocking” will receive a badge in that specialty. Future employers have greater confidence in the worker’s qualifications, and can even mark certain jobs as eligible to only badge-holders. Think of it as a hybrid between Google Maps Reviews + Duolingo Badges, for individual workers. The system is proven to work, with >90% of positive reviews and just a 0.1% “no-show” rate. Importantly for workers, the payment is processed quickly after the shift (often same-day). In contrast, part-time jobs are conventionally paid the following month in Japan – weeks after the job finished. In this way, Timee addresses a crucial pain point of temp work – especially as households face rising inflation and strained budgets. For background, Japan is facing structural inflation for the first time in decades – rising to >3% vs. 3x upside over a few years as revenues grow in the low-20% range and margins march toward 30%+, with additional optionality from new verticals, fintech adjacencies, and eventual international expansion. Execution risks include macro labor softness, regulatory changes in gig work, and potential new competition, but the current valuation and demonstrated competitive moat make the risk-reward attractive.